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Workﬂow analysisThe performance characteristics of rapid inﬂuenza diagnostic tests vary widely. This study evaluated the BD
Veritor™ System Flu A+B (Veritor; BD Diagnostics, Sparks, MD, USA), Quidel® Soﬁa® Inﬂuenza A+B FIA (Soﬁa;
Quidel Corp., San Diego, CA, USA), and Alere BinaxNOW® Inﬂuenza A&B (Binax; Alere Scarborough, Inc.,
Scarborough, ME, USA) compared to reverse transcription-polymerase chain reaction (RT-PCR) for detection of
inﬂuenza viruses in nasal wash specimens from240 pediatric patients. Positive percent agreements for inﬂuenza
A and B virus detectionwere 93.8% and 94.2%, 95.8% and 98.1%, and 79.2% and 80.8% for Veritor, Soﬁa, and Binax,
respectively. The Veritor and Binax tests demonstrated negative percent agreements N97.9% for detection of both
inﬂuenza viruses, but the negative percent agreement of the Soﬁa test was 91.1% for inﬂuenza A and 70.7% for
inﬂuenza B virus. Overall, the Veritor and Soﬁa tests were nearly as sensitive as RT-PCR and considerably more
sensitive than Binax for detection of inﬂuenza viruses. However, the accuracy of the Soﬁa test was signiﬁcantly
lower than either Veritor or Binax.
© 2014 The Authors. Published Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Inﬂuenza virus infections are responsible for signiﬁcant morbidity
and mortality in both pediatric and adult populations worldwide.
Unfortunately, inﬂuenza infection is difﬁcult to recognize based solely
on clinical symptoms (Poehling et al., 2006). Establishing inﬂuenza as
the viral etiology of infection is highly dependent on accurate
diagnostic testing. Rapid and accurate diagnosis of inﬂuenza virus
infection is of medical importance for clinical patient management,
initiation of antiviral therapy, reduction of additional diagnostic
studies, discontinuation of the use of unnecessary antibiotics, and
institution of infection control practices (Barenfanger et al., 2000;
Bonner et al., 2003; Henrickson, 2005; Sharma et al., 2002; Woo et al.,
1997). Rapid tests for the detection of inﬂuenza virus are amenable for
use in physicians' ofﬁces or small laboratories that lack more complex
viral diagnostic capabilities.
Commercially available rapid inﬂuenzadiagnostic tests (RIDTs) have
a broad range of sensitivities for detection of seasonal, pandemic, and
novel inﬂuenza virus infections (Baas et al., 2013; Chan et al., 2013;
Chartrand et al., 2012; CDC, 2012; Dunn et al., 2003; Ginocchio et al.,
2009), whereas RT-PCR has demonstrated superior sensitivity for
detection of inﬂuenza viruses (Freymuth et al., 2006; Kuypers et al.,
2006;Weinberg et al., 2004). TheBDVeritor™ SystemFluA+B(Veritor;+1-682-885-6111.
n).
c.Open access under CC BY-NC-ND licBDDiagnostics, Sparks,MD,USA) is a digital immunoassay for direct and
qualitative detection and differentiation of inﬂuenza A and B viruses
using nasopharyngeal (NP)wash, aspirate, and swab in transportmedia
samples from symptomatic patients. TheQuidel® Soﬁa® Inﬂuenza A+B
FIA (Soﬁa; Quidel Corp., San Diego, CA, USA) detects and differentiates
inﬂuenza A and B viruses using immunoﬂuorescent technology to
qualitatively identify virus-speciﬁc nucleoprotein antigens in nasal
swabs, NP swabs, and NP aspirates or washes. Results from both the
Veritor and Soﬁa assays are analyzed and interpreteddigitallywith their
respective readers. These digital immunoassays (DIAs) enable lower
limits of detection (LODs) due to a low cut-off, reduce operator
variability, and allow for a negative control that reduces the probability
of non-speciﬁc binding. The objective, qualitative result of the DIAs
potentially enables use of these assays outside the central laboratory
environment. The Alere BinaxNOW® Inﬂuenza A&B (Binax; Alere
Scarborough, Inc., Scarborough, ME, USA) immunochromatographic
assay qualitatively detects inﬂuenza A and B nucleoprotein antigens in
nasal swabs, NP swabs, and nasal wash or aspirate specimens, and the
resulting color change is read visually and interpreted by the operator.
This study is the ﬁrst head-to-head evaluation of the performance and
workﬂowof the BDVeritor™ SystemFluA+B, Quidel®Soﬁa® Inﬂuenza
A+B FIA, and Alere BinaxNOW® Inﬂuenza A&B in vitro assays.
2. Materials and methods
A total of 240 excess nasal wash specimens submitted for routine
inﬂuenza testing and with sufﬁcient residual volume for all tests wereense.
Table 1
Primers and probes for ampliﬁcation and detection of inﬂuenza A, inﬂuenza B, and A/pH1N1 subtyping.
Description Name Sequence (5′ to 3′) Target
Inﬂuenza A forward primer FluA-F1 TCATGGAGTGGCTAAAGACAAGAC Matrix (M)
Inﬂuenza A forward primer FluA-F2 TCATGGAATGGCTAAAGACAAGAC
Inﬂuenza A reverse primer FluA-R GGCACGGTGAGCGTGAA
Inﬂuenza A probe FluA-Probe (FAM)-TCACCTCTGACTAAGGG-(MGB)
Inﬂuenza B forward primer FluB-F AAATACGGTGGATTAAACAAAAGCAA Hemagglutinin (HA)
Inﬂuenza B reverse primer FluB-R CCAGCAATAGCTCCGAAGAAA
Inﬂuenza B probe FluB-Probe (TAMRA)-CACCCATATTGGGCAATTTCCTATGGC-(BHQ2)
A/pH1N1 forward primer H1-F TGTGAATCACTCTCCACAGCAAGC Hemagglutinin (HA)
A/pH1N1 reverse primer H1-R ATTGGGCCATGAACTTGTCTTGGG
A/pH1N1 probe H1-Probe (Quasar670)-CAGACAATGGAACGTGTTACCCAGGA-(BHQ2)
11J. Dunn et al. / Diagnostic Microbiology and Infectious Disease 79 (2014) 10–13analyzed using the Food and Drug Administration (FDA)–cleared BD
Veritor System Flu A+B (laboratory kit for use with liquid samples),
Quidel Soﬁa Inﬂuenza A+B FIA, and Alere BinaxNOW Inﬂuenza A&B
card per the manufacturer's instructions. Specimens were collected
from symptomatic patients under 18 years of age between the dates of
January 23, 2013, and April 5, 2013, by installation of 2–5 mL normal
saline into the nasal cavity, retrieval of the wash ﬂuid using a bulb
syringe or similar device and placed in a sterile container. Specimens
were transported to the laboratory immediately and either tested
upon receipt or stored at 4 °C and tested within 24 hours.
For analysis by RT-PCR, viral RNA was extracted using the
NucliSENS® easyMAG® instrument (bioMérieux, Inc., Durham, NC,
USA) from 200 μL of nasal wash specimen per the manufacturer’s
directions and eluted in a volume of 60 μL. Multiplex RT-PCR for
inﬂuenza A and Bwas performed in a 25-μL reaction volume on a 7500
real-time PCR system (Applied Biosystems, Foster City, CA, USA) using
5 μL of eluted nucleic acid; 12.5 μL QuantiTect Probe RT-PCR Master
Mix (Qiagen, Germantown, MD, USA); 0.25 μL QuantiTect RT Mix
(Qiagen); 1.25 μL human β-glucuronidase endogenous internal
control reagent (Applied Biosystems); 1 U heat labile UNG (Roche
Diagnostics, Indianapolis, IN); 300 nmol/L each inﬂuenza A primer,
600 nmol/L each inﬂuenza B and A/pH1N1 primer, 150 nmol/L
inﬂuenza A probe, 300 nmol/L inﬂuenza B and A/pH1N1 probes;
universal ampliﬁcation conditions consisting of 1 cycle for 10 min at
20 °C, 1 cycle for 30 min at 50 °C, and 1 cycle for 15 min at 95 °C
followedby 45 two-step cycles of 15 s at 95 °C and1min at 60 °C (Dunn
et al., 2012). A result was considered positive if the inﬂuenza virus
target cycle threshold (Ct) was b40 and negative if only the
endogenous internal control was detected with Ct b40. Positive and
negative controls were processed with each batch of clinical
specimens from extraction of nucleic acids through the detection of
ampliﬁed products. No-template controls were included in each
reaction plate for all sets of primers and probes. Primer and probe
sequences targeted conserved regions of the inﬂuenza A and B genome
(Table 1) and were based on the published literature (Kuypers et al.,
2006; vanEldenet al., 2001;Wanget al., 2009). The analytical sensitivity
or LOD of the multiplex RT-PCR assay was previously determined to be
101.3 TCID50/mL for inﬂuenza A/California/04/2009 (A/pH1N1), 101.5
TCID50/mL for inﬂuenza A/Hong Kong/08/68 (A/H3N2), and 101.2
TCID50/mL for inﬂuenza B/Lee/40 (unpublished data).Table 2
Performance characteristics of the Veritor, Soﬁa, and Binax RIDTs compared to RT-PCR.
Inﬂuenza type RIDT Positive agreement (%) (95% CI) Negative agreem
A Veritor 45/48, 93.8% (81.8–98.4) 188/192, 97.9%
Soﬁa 46/48, 95.8% (84.6–99.3) 175/192, 91.1%
Binax 38/48, 79.2% (64.6–89.0) 191/192, 99.5%
B Veritor 49/52, 94.2% (83.1–98.5) 188/188, 100% (
Soﬁa 51/52, 98.1% (88.4–99.9) 133/188, 70.7%
Binax 42/52, 80.8% (67.0–89.9) 187/188, 99.5%
CI = conﬁdence interval.For workﬂow analyses, 3 time andmotion studies were performed
to collect the following metrics: i) total cycle time (i.e., the amount of
time required to perform testing on a batch of 10 specimens as well as
discrete processing of a single specimen, including all manual and
automated pre-analytical, analytical, and post-analytical activities), ii)
total processing steps (i.e., the number of steps required to perform
testing across 10 specimens), iii) hands-on time (i.e., the amount of
time that lab personnel must devote to physically performing testing),
and iv) automated/dwell time (i.e., the amount of time that testing
was being performed but the operator was not actively engaged in
hands-on testing activities).
Three batches of 10 specimens were analyzed by a single
experienced technologist using the Veritor, Soﬁa, and Binax test
methods, and a regression analysis was performed to ensure
consistency in the measurements collected and processes documen-
ted. Time and process measurements were collected and analyzed
from the time the specimenswere placed on the processing counter to
the time that actionable results were generated. Measurements were
compared to each manufacturer’s package insert to ensure processing
adhered to manufacturer guidelines.
3. Results
One hundred nasal wash specimens tested positive for an
inﬂuenza virus by RT-PCR, 48 inﬂuenza A and 52 inﬂuenza B.
Compared to RT-PCR, the Veritor correctly identiﬁed inﬂuenza A in
45 specimens (93.8% positive agreement) and inﬂuenza B in 49
specimens (94.2% positive agreement). The Soﬁa assay was positive
for 46 of 48 specimens with inﬂuenza A (95.8% positive agreement)
and 51 of 52 specimens with inﬂuenza B (98.1% positive agreement).
The Binax assay correctly identiﬁed inﬂuenza A in 38 specimens
(79.2% positive agreement) and inﬂuenza B in 42 specimens (80.8%
positive agreement). Nine specimens were subtyped as A/pH1N1 by
multiplex RT-PCR testing. All 9 were detected by the Soﬁa and Veritor
assays, while only 6 were detected by Binax. The presence of inﬂuenza
A/H3N2 was not conﬁrmed as the RT-PCR assay did not speciﬁcally
differentiate this subtype. There were 4, 17, and 1 false-positive
results for inﬂuenza A virus when tested by Veritor, Soﬁa, and Binax,
respectively. The negative percent agreement for the Veritor and
Binax assays were 97.9% and 99.5%, respectively, for inﬂuenza A virusent (%) (95% CI) PPV (%) (95% CI) NPV (%) (95% CI)
(94.4–99.3) 45/49, 91.8% (79.5–97.4) 188/191, 98.4% (95.1–99.6)
(86.0–94.6) 46/63, 73.0% (60.1–83.1) 175/177, 98.9% (95.5–99.8)
(96.7–100) 38/39, 97.4% (84.9–99.9) 191/201, 95.0% (90.8–97.5)
97.5–100) 49/49, 100% (90.9–100) 188/191, 98.4% (95.1–99.6)
(63.6–77.0) 51/106, 48.1% (38.4–58.0) 133/134, 99.3% (95.3–100)
(96.6–100) 42/43, 97.7% (86.2–99.9) 187/197, 94.9% (90.6–97.4)
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91.1% for inﬂuenza A virus, and the predictive value of a positive result
was 73.0%. Soﬁa testing generated 55 false-positive inﬂuenza B results
(70.7% negative agreement) resulting in a positive predictive value
(PPV) of 48.1% and 76.7% accuracy. Binax showed 1 false positive for
inﬂuenza B virus (99.5% negative agreement), and none were
observed using the Veritor (100% negative agreement). Overall
performance characteristics for the Veritor, Soﬁa, and Binax tests
relative to RT-PCR are shown in Table 2.
A workﬂow comparison study was carried out to determine the
amount of hands-on and dwell time needed to perform a batch size of
ten specimens or a single test with each assay (Fig. 1). Testing of 10
specimens was completed in 18.1, 35.5, and 24.4 min for the Veritor,
Soﬁa, and Binax, respectively. Single specimens were completed in
10.7, 17.7, and 16.1 min for the Veritor, Soﬁa, and Binax, respectively.
4. Discussion
Timely and accurate diagnosis of inﬂuenza virus infections is
important for patient management. Testing is recommended for a
number of patient populations in whom a rapid result could inﬂuence
medical decision making such as the need for initiation of antiviral
therapy, discontinuation of antibiotics, institution of infection control
practices, and hospitalization (Harper et al., 2009). To that end, RIDTs
have been utilized for a number of years in a variety of settings.
Generally, positive results by these rapid methods correlate well with00:00
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Fig. 1. Workﬂow comparison for testing of a single specimen (A) or a batch size of 10
specimens at one time (B). Total test times are noted at the top of each bar graph.actual inﬂuenza virus infection. However, due to the typically low
sensitivities and negative predictive values (NPVs) of rapid tests,
conﬁrmatory testing with more sensitive methods such as RT-PCR or
culture has been recommended (Chartrand et al., 2012; Harper et al.,
2009). An ideal RIDT would have diagnostic accuracy approaching or
equivalent to the more sensitive methods. Unfortunately, the
performance characteristics of rapid tests vary widely depending on
factors such as patient age, duration of illness, specimen type, and
strain of virus.
This study demonstrated that the Veritor and Soﬁa, both digital
immunoassays, had positive agreements N93.8% for detection of
inﬂuenza A and B viruses in pediatric nasal wash specimens when
compared to RT-PCR (Table 2). However, the PPVs observedwith Soﬁa
testingwere signiﬁcantly lower than those seenwithVeritor andBinax
testing due to false positives for both inﬂuenza A (n = 17) (PPV =
73.0%) and inﬂuenza B (n = 55) (PPV = 48.1%). The manufacturer of
the Soﬁa test issued a recall on speciﬁc lots on December 3, 2012, due
to issues with false-positive results (Soﬁa Inﬂuenza A+B Test, 2013).
However, none of the affected lots were used in this study. The false-
positive Soﬁa results of our study contrast starkly with those of other
recent studies in which PPVs for inﬂuenza A and B detection were
97.4% and 91.7%, respectively, compared to RT-PCR (Lewandrowski
et al., 2013) and 100% for both virus types compared to culture (Lee
et al., 2012). It is possible that these studies utilized assay kit lots that
were manufactured prior to the 2012–2013 respiratory virus season
and were unaffected by the product recall. In fact, our initial clinical
evaluation of the Soﬁa test during the 2011–2012 respiratory virus
season revealed PPVs of 97.9% for inﬂuenza A and 92.3% for inﬂuenza B
(Dunn et al., 2012).
In general, the positive agreements of the 3 diagnostics tests with
RT-PCR in this study were higher than the reported sensitivities of
some of these assays compared to RT-PCR in other studies; perhaps
due to the age of the patient population and specimen type collected.
In a study comprised mostly of specimens from pediatric patients
comparing the Soﬁa assay to RT-PCR, the sensitivity of rapid testing
for inﬂuenza A and B was 78% and 86%, respectively (Lewandrowski
et al., 2013). However, the respiratory specimens in that study were
collected in viral transport media (VTM), which could potentially
dilute the concentration of antigen present in the sample prior to
testing. Likewise, the overall sensitivity of the Binax test for detection
of both inﬂuenza A and B compared to RT-PCR using NP swabs in VTM
was 52.6% in a pediatric population (Landry et al., 2008). In our study,
nasal wash specimens were tested directly without addition of
VTM, potentially accounting for a better performance observed for
these RIDTs.
The ability to detect novel inﬂuenza A virus strains has been of
concern for both public health purposes as well as management of
individual patients. An evaluation of FDA-cleared RIDTs to detect 7
different clinical isolates of inﬂuenza A variant (H3N2v) virus
showed that both the Veritor and Soﬁa assays reliably detected
several serial 10-fold dilutions of these strains, whereas the Binax
assay was up to 4 log-fold less sensitive (CDC, 2012). The Veritor
and Soﬁa assays were capable of detecting avian origin inﬂuenza A
(H7N9) virus at a concentration of 1.6 × 105 TCID50/mL, whereas the
LOD for the Binax assay was 5.0 × 105 TCID50/mL (Baas et al., 2013).
In another study, the LODs for inﬂuenza A (H7N9) for the Veritor
and Soﬁa assays were N1 log-fold dilution lower than 5 other RIDTs
as well as 2 commercially available multiplex molecular assays (Chan
et al., 2013). The Veritor assay has also been shown to be 8- to 32-fold
more sensitive than the Binax assay when assessed in vitro using
dilutions of stock virus preparations of 2009 inﬂuenza A (H1N1)
inﬂuenzaA (H3N2), and inﬂuenzaBVictoria lineage (Peters et al., 2013).
Laboratory workﬂow analysis was performed with each diagnostic
test using clinical specimens to assess the efﬁciency and turn-around
time of testing with either a single sample or a batch of 10 clinical
specimens at one time (Fig. 1). Of note, once the specimen is added to
13J. Dunn et al. / Diagnostic Microbiology and Infectious Disease 79 (2014) 10–13the cartridge, themanufacturer’s package inserts state that incubation
should occur for 10 min, 15 min, and 15 min for the Veritor, Soﬁa, and
Binax assays, respectively. Thus, analyses of single specimen testing
did not require much additional time beyond the duration of
incubation, hands-on times of 34 s, 63 s, and 100 s for Veritor,
Binax, and Soﬁa, respectively. The digital reader for Veritor takes
approximately 10 s to generate a result, whereas the Soﬁa reader
requires up to 1 min. With batch testing analyses, the Veritor and
Binax required approximately the same amount of hands-on time at
~10.1min, whereas the dedicated time for Soﬁa testingwasmore than
twice as long at 27.6 min. During the busy respiratory season, the
impact of a faster turn-around time and reduced hands-on time
makes this characteristic an important component in the selection of a
diagnostic inﬂuenza virus assay. Overall, in terms of workﬂow and
performance characteristics, the Veritor provided the most rapid test
results for inﬂuenza A and B viruses with the greatest accuracy (i.e.,
the proportion of all tests that are correct) compared to RT-PCR,
followed by Binax then Soﬁa.
Acknowledgments
This work was supported in part by BD Diagnostics.
References
Baas C, Barr IG, Fouchier RA, Kelso A, Hurt AC. A comparison of rapid point-of-care tests
for the detection of avian inﬂuenza A(H7N9) virus, 2013. Euro Surveill 2013;18:
pii=20487.
Barenfanger J, Drake C, Leon N, Mueller T, Troutt T. Clinical and ﬁnancial beneﬁts of
rapid detection of respiratory viruses: an outcomes study. J Clin Microbiol 2000;38:
2824–8.
Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid
diagnosis of inﬂuenza on physician decision-making and patient management in
the pediatric emergency department: results of a randomized, prospective,
controlled trial. Pediatrics 2003;112:363–7.
Centers for Disease Control and Prevention (CDC). Evaluation of rapid inﬂuenza diagnostic
tests for inﬂuenza A (H3N2)v virus and updated case count–United States, 2012.
MMWRMorb Mortal Wkly Rep 2012;61:619–21.
Chan KH, To KKW, Chan JFW, Li CPY, Chen H, Yuen KY. Analytical sensitivity of seven
point-of-care inﬂuenza virus detection tests and two molecular tests for detection
of avian origin H7N9 and swine origin H3N2 variant inﬂuenza A viruses. J Clin
Microbiol 2013;51:3160–1.
Chartrand C, Leeﬂang M, Minion J, Brewer T, Pai M. Accuracy of rapid inﬂuenza
diagnostic tests: a meta-analysis. Ann Intern Med 2012;156:500–11.
Dunn JJ, Gordon C, Kelley C, Carroll KC. Comparison of the Denka-Seiken INFLU AB-
Quick and BD Directigen Flu A+B kits with direct ﬂuorescent-antibody staining andshell vial culture methods for rapid detection of inﬂuenza viruses. J Clin Microbiol
2003;41:2180–3.
Dunn JJ, Obuekwe JA, Baun T, Abell P, Patel T, Singleton M, et al. Performance of the
rapid Quidel Soﬁa Inﬂuenza A+B FIA compared to the BinaxNOW Inﬂuenza A&B
assay and real time RT-PCR for detection of pediatric inﬂuenza virus infections,
abstr S-23. Abstr 28th Annu Clin Virol Symp; 2012.
Freymuth F, Vabret A, Cuvillon-Nimal D, Simon S, Dina J, Legrand L, et al. Comparison of
multiplex PCR assays and conventional techniques for the diagnostic of respiratory
virus infections in children admitted to hospital with an acute respiratory illness.
J Med Virol 2006;78:1498–504.
Ginocchio CC, Zhang F, Manji R, Arora S, Bornfreund M, Falk L, et al. Evaluation of
multiple test methods for the detection of the novel 2009 inﬂuenza A(H1N1)
during the New York City outbreak. J Clin Virol 2009;45:191–5.
Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal
inﬂuenza in adults and children—diagnosis, treatment, chemoprophylaxis, and
institutional outbreak management: clinical practice guidelines of the Infectious
Diseases Society of America. Clin Infect Dis 2009;48:1003–32.
Henrickson KJ. Cost-effective use of rapid diagnostic techniques in the treatment and
prevention of viral respiratory infections. Pediatr Ann 2005;34:24–31.
Kuypers J, Wright N, Ferrenberg J, Huang ML, Cent A, Corey L, et al. Comparison of real-
time PCR assays with ﬂuorescent-antibody assays for diagnosis of respiratory virus
infections in children. J Clin Microbiol 2006;44:2382–8.
Landry ML, Cohen S, Ferguson D. Real-time PCR compared to Binax NOW and cytospin-
immunoﬂuorescence for detection of inﬂuenza in hospitalized patients. J Clin Virol
2008;43:148–51.
Lee CK, Cho CH, Woo MK, Nyeck AE, Lim CS, Kim WJ. Evaluation of Soﬁa ﬂuorescent
immunoassay analyzer for inﬂuenza A/B virus. J Clin Virol 2012;55:239–43.
Lewandrowski K, Tamerius J, Menegus M, Olivo PD, Lollar R, Lee-Lewandrowski E.
Detection of inﬂuenza A and B viruses with the Soﬁa analyzer. Am J Clin Pathol
2013;139:684–9.
Peters TR, Blakeney E, Vannoy L, Poehling KA. Evaluation of the limit of detection of the
BD Veritor system ﬂu A+B test and two rapid inﬂuenza detection tests for
inﬂuenza virus. Diagn Microbiol Infect Dis 2013;75:200–2.
Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The
underrecognized burden of inﬂuenza in young children. N Engl J Med 2006;355:
31–40.
Sharma V, DowdMD, Slaughter AJ, Simon SD. Effect of rapid diagnosis of inﬂuenza virus
type A on the emergency department management of febrile infants and toddlers.
Arch Pediatr Adolesc Med 2002;156:41–4.
Soﬁa Inﬂuenza A+B Test. Biomedical Safety & Standards 2013;43:60. doi:10.1097/01.
BMSAS.0000429466.90287.7f.
van Elden LJR, Nijhuis M, Schipper P, van Loon AM. Simultaneous detection of
inﬂuenza A and B viruses using real-time quantitative PCR. J Clin Microbiol 2001;
39:196–200.
Wang R, Sheng ZM, Taubenberger JK. Detection of novel (swine origin) H1N1 inﬂuenza
A virus by quantitative real-time reverse transcription-PCR. J Clin Microbiol
2009;47:2675–7.
Weinberg GA, Erdman DD, Edwards KM, Hall CB, Walker FJ, GrifﬁnMR, et al. Superiority
of reverse-transcription polymerase chain reaction to conventional viral culture in
the diagnosis of acute respiratory tract infections in children. J Infect Dis 2004;189:
706–10.
Woo P, Chiu S, SetoW, Peiris M. Cost-effectiveness of rapid diagnosis of viral respiratory
tract infections in pediatric patients. J Clin Microbiol 1997;35:1579–81.
